KEY TAKEAWAYS
- CONTACT-02 is a phase III clinical trial that evaluates the comparative efficacy of cabozantinib + atezolizumab vs. other neoadjuvant hormonal therapies.
- The trial’s primary aim is to determine if the combination of cabozantinib and atezolizumab improves overall survival compared to other NHTs in patients.
- The trial methodology includes randomizing eligible patients to receive either cabozantinib + atezolizumab or NHT.
- The trial outcome will be determined by assessing overall survival and disease-free survival in the two treatment groups.
- The trial is particularly important for individuals with advanced mCRPC who have progressed following treatment with enzalutamide.
- The trial has been registered on ClinicalTrials.gov with the identifier NCT04446117 and is ongoing
The broad-spectrum receptor tyrosine kinase inhibitory properties of cabozantinib, particularly those associated with the TAM kinase family, are expected to augment the efficacy of checkpoint inhibitors by enhancing the immune system response. In the ongoing phase, Ib investigation for COSMIC-021 (NCT03170960), a potential benefit has been observed in a cohort of men with metastatic castration-resistant prostate cancer (mCRPC) that has progressed in soft tissue following therapy with enzalutamide and/or abiraterone for metastatic disease. The COSMIC-021 research team is carrying out the study in question. This cohort of male patients has progressed to an advanced stage of soft tissue following treatment for metastatic disease with enzalutamide and/or abiraterone. The ongoing research project aims to evaluate the efficacy of a combined therapeutic approach involving cabozantinib and atezolizumab, a PD-L1 inhibitor.
The population of patients who have previously undergone treatment with NHT for mCRPC, metastatic castration-sensitive PC, or nonmetastatic CRPC is in great need of additional treatment options. The individuals in question exhibit either visceral ailment or extrapelvic adenopathy, indicative of progressed prostate carcinoma. In this article, we shall analyze the rationale behind a phase III clinical trial juxtaposing the administration of cabozantinib + atezolizumab against an alternative novel hormone treatment (NHT) alongside a detailed exposition of the study’s design and methodologies. The study evaluated the comparative efficacy of cabozantinib + atezolizumab versus other neoadjuvant hormonal therapies.
Source: https://pubmed.ncbi.nlm.nih.gov/35034502/
Clinical Trail: https://clinicaltrials.gov/ct2/show/NCT04446117
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, Pal S. A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncol. 2022 Mar;18(10):1185-1198. doi: 10.2217/fon-2021-1096. Epub 2022 Jan 17. PMID: 35034502.
